HESKA CORPORATION (NASDAQ:HSKA) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
The information in this current report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
On February 28, 2018, Heska Corporation announced its financial results for the quarter and year ended December 31, 2017 and certain other information. A copy of the press release announcing these financial results and certain other information is attached hereto as Exhibit 99.1.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
The following exhibit is furnished with this current report on Form 8-K:
Exhibit No.Exhibit Description
HESKA CORP ExhibitEX-99.1 2 ex99-1earningsreleaseq4and.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Heska Corporation: Hayden IR:Jon Aagaard Brett Maas Director,…To view the full exhibit click here
About HESKA CORPORATION (NASDAQ:HSKA)
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It offers blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.
